[HTML] sciencedirect.com

[HTML][HTML] Phase I trial of the oral poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888, V) combined wtih topoecan (T) and carboplatin (C) for adults with …

KW Pratz, SH Kaufmann, MR Litzow, J Ji, A Chen… - Blood, 2011 - Elsevier
Abstract 3634 PARP is activated in response to DNA single strand (SS) breaks and is pivotal
to the base excisional repair pathway for chemotherapy-damaged DNA. The orally …
被引用次数：3 相关文章 所有 2 个版本

Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with …

JE Karp, KW Pratz, MR Litzow, J Ji, A Chen, M Rudek… - Blood, 2010 - Elsevier
Abstract 3276 PARP is activated in response to DNA single strand (SS) breaks and is pivotal
to the base excisional repair pathway for chemotherapy-damaged DNA. The orally …
被引用次数：1 相关文章 所有 2 个版本

Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in …

P LoRusso, JJ Ji, J Li, LK Heilbrun… - Journal of Clinical …, 2011 - ascopubs.org
3000 Background: The nuclear enzyme PARP is essential in recognition and repair of DNA
damage. In preclinical models, PARP inhibitors work as sensitizing agents for DNA …
被引用次数：41 相关文章
[HTML] nih.gov

Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

LJ Appleman, JH Beumer, Y Jiang, Y Lin… - Cancer chemotherapy …, 2019 - Springer
Purpose Veliparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP)-1 and-2.
PARP-1 expression may be increased in cancer, and this increase confers resistance to …
被引用次数：33 相关文章 所有 8 个版本

Phase I study of ABT-888 in combination with carboplatin and gemcitabine in subjects with advanced solid tumors.

KM Bell-McGuinn, HJ Gray, GF Fleming, MC Cristea… - 2013 - ascopubs.org
2584^ Background: Veliparib (V) is an oral inhibitor of poly (ADP-ribose) polymerases
(PARP)-1 and-2, which are essential for base excision repair of ssDNA breaks. BRCA …
被引用次数：16 相关文章
[HTML] sciencedirect.com

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias

I Gojo, JH Beumer, K Pratz, J Ji, L Wang, MA Rudek… - 2015 - ashpublications.org
Among mechanisms underlying cytotoxic drug resistance is activation of diverse DNA
damage response (DDR) pathways. Poly (ADP-ribose) polymerases (PARP)-1/2 facilitate …
被引用次数：2 相关文章 所有 2 个版本
[HTML] nih.gov

Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan …

PM LoRusso, J Li, A Burger, LK Heilbrun… - Clinical Cancer …, 2016 - AACR
Purpose: PARP is essential for recognition and repair of DNA damage. In preclinical models,
PARP inhibitors modulate topoisomerase I inhibitor–mediated DNA damage. This phase I …
被引用次数：99 相关文章 所有 5 个版本

A phase I trial of veliparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), and topotecan (TPT) in patients with solid tumors.

AE Wahner Hendrickson, ME Menefee, LC Hartmann… - 2015 - ascopubs.org
TPS2618 Background: PARPs are a highly conserved family of enzymes whose
predominant function is to preserve genomic integrity following DNA damage. Preclinical …
被引用次数：2 相关文章
[HTML] nih.gov

A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia

I Gojo, JH Beumer, KW Pratz, MA McDevitt… - Clinical Cancer …, 2017 - AACR
Purpose: In preclinical studies, the PARP inhibitor veliparib enhanced the antileukemic
action of temozolomide through potentiation of DNA damage. Accordingly, we conducted a …
被引用次数：71 相关文章 所有 9 个版本

Phase I trial of veliparib,(ABT-888), a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and …

AR Tan, D Toppmeyer, MN Stein, RA Moss… - Journal of Clinical …, 2011 - ascopubs.org
3041 Background: Veliparib is a potent, oral inhibitor of PARP-1 and PARP-2. We previously
reported phase I results of veliparib and cyclophosphamide (C). Evaluation of veliparib and …
被引用次数：47 相关文章